Magnolol triggers ferroptosis in triple-negative breast cancer through modulation of the ETS2/SLC7A11/GPX4 signaling axis
Frontiers in Pharmacology · 31.07.2026 · 17
DOI: 10.3389/fphar.2026.1876648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.07.2026. Verfasst von Jing Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Bengbu Medical University, Bengbu, China. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation (LPO), represents a promising therapeutic strategy. Magnolia officinalis , a traditional herb for resolving dampness and phlegm, is known to modulate cellular metabolism. While magnolol (MAG), a bioactive neolignan from M. officinalis , shows anti-TNBC activity, its role in inducing ferroptosis remains unexplored.
Methods
Anti-TNBC effects of MAG were assessed in MDA-MB-231 and 4T1 cells via viability, apoptosis, and ferroptosis assays (intracellular Fe 2+ , LPO, GSH). Target identification employed network pharmacology, RNA-seq, surface plasmon resonance, and pull-down assays. Mechanisms were validated using siRNA/overexpression, Co-IP, and immunofluorescence. In vivo efficacy was evaluated in xenograft models.
Results
MAG inhibited proliferation and induced apoptosis and ferroptosis in TNBC cells, evidenced by elevated Fe 2+ and lipid peroxidation, depleted GSH, downregulated SLC7A11/GPX4, and mitochondrial shrinkage effects reversed by ferroptosis inhibitors. MAG directly bound and suppressed transcription factor ETS2. ETS2 knockdown sensitized cells to MAG-induced ferroptosis, while its overexpression restored SLC7A11/GPX4 expression and conferred resistance. Mechanistically, ETS2 transcriptionally regulated SLC7A11, and MAG enhanced ETS2-SLC7A11 protein interaction. In vivo , MAG significantly suppressed tumor growth with low toxicity and downregulated ETS2, SLC7A11, and GPX4.
Conclusion
MAG induces ferroptosis in MDA-MB-231 cells, which may be mediated by targeting the ETS2/SLC7A11/GPX4 signaling axis, providing mechanistic insights into its anti-TNBC activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Bengbu Medical University, Bengbu, China.
- Anhui Province Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu, China.
- School of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China.
Zitieren
APA
Zhu, J., Zhong, K., Zhuang, Y., Cai, A., Zhou, Y. H., Yuan, J., Ding, F., Zhao, L., Zhang, Y. X., Li, B. H., Wu, C. Z., & Li, H. M. (2026). Magnolol triggers ferroptosis in triple-negative breast cancer through modulation of the ETS2/SLC7A11/GPX4 signaling axis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1876648
Vancouver
Zhu J, Zhong K, Zhuang Y, Cai A, Zhou YH, Yuan J, et al. Magnolol triggers ferroptosis in triple-negative breast cancer through modulation of the ETS2/SLC7A11/GPX4 signaling axis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1876648
BibTeX
@article{Zhu2026,
author = {Zhu, Jing and Zhong, Ke and Zhuang, Yan and Cai, Ao and Zhou, Yu-Han and Yuan, Jie and Ding, Feng and Zhao, Long and Zhang, Yu-Xin and Li, Bo-Han and Wu, Cheng-Zhu and Li, Hong-Mei},
title = {Magnolol triggers ferroptosis in triple-negative breast cancer through modulation of the ETS2/SLC7A11/GPX4 signaling axis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1876648}
}
EUVIMED